Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on ...

Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Although primarily used to prevent tuberculosis, the BCG vaccine is also a standard treatment for some forms of bladder cancer. In the past year, shares of Pfizer have lost nearly 7% compared with ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-naïve, high-risk, non-muscle invasive bladder ...

Jan 10 (Reuters) - Pfizer's (PFE.N), opens new tab experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications ...